WHC is still in active development. Read this to understand our approach.
depiction of VMWNQDUVQKEIOC-UHFFFAOYSA-N.svg
isomerdesign

Apomorphine

Verificar en isomerdesign

pubchem

Apomorphine

Verificar en pubchem

drugmap

Apomorphine

Verificar en drugmap

drugmap

Apomorphine

Verificar en drugmap

wiki

Apomorphine

Verificar en wiki

Data

InChI: InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3

Sinónimos: APOMORPHINE6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol,(9R)-10-methyl-10-azatetracyclo[7.7.1.0?,?.0??,??]heptadeca-1(16),2,4,6,13(17),14-hexaene-3,4-diol,N21FAR7B4S,EN300-18161186, ZINC155525,Apomorphine hydrochloride hemihydrate,DTXSID8022614,Prestwick0_000101,HMS2089C10,NCGC00025349-05,NCGC00025349-03,(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol,NCGC00025349-01, cid_6852389,41372-20-7,Apomorphine (R,-),APOMORPHINE [WHO-DD],PDSP2_001488,Tox21_110967,BSPBio_000082,EINECS 200-360-0,(R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol ((R)-apomorphine),NCGC00025349-02, UNII-LH812IV7LI, Apomorphine, S-,HSDB 3289,DSSTox_CID_2614,DSSTox_RID_76660,VR040,apomorphine,372A207,D07460,BPBio1_000092,(R)-5,6,6A,7-TETRAHYDRO-6-METHYL-4H-DIBENZO[DE-G]QUINOLINE-10,11-DIOL, (6as)-10,11-dihydroxyaporphine,APOMORPHINE [MI],Prestwick1_000101, S(+)-APOMORPHINE,SCHEMBL8541, GTPL8285, Lopac-A-4393,Apomorphinium chloride hemihydrate,L-Apomorphine,Apomorphine (intranasal, Parkinson's disease),6a-beta-Aporphine-10,11-diol,Apokyn,(S)APOMORPHINE,Apomorphine free base,Tox21_110967_1, CTK1C3986,ZINC9073,(R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol,BRD-K76022557-311-20-6,6abeta-Aporphine-10,11-diol, AC1LEHBI,5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo-[de,g]quinoline-10,11-diol,Tocris-2073,(6aR)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo(de,g)chinolin-10,11-diol,SMP1_000027, DTXSID40192615,Apomorphinum, PDSP1_001504, LH812IV7LI,BPBio1_001179,CAS-58-00-4,(6AR)-5,6,6A,7-TETRAHYDRO-6-METHYL-4H-DIBENZO(DE,G)QUINOLINE-10,11-DIOL, Oprea1_044402,(R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol(apomorphine),(-)6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol(APO),6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol((R)-apomorphine),(R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol, CHEMBL416288, (+)-10,11-Dihydroxyaporphine,58-00-4,PDSP1_000780,APOMORPHINUM [HPUS],APL-130277,Ixense,(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrate;hydrochloride,Q269111,(9R)-10-methyl-10-azatetracyclo[7.7.1.0^{2,7}.0^{13,17}]heptadeca-1(16),2(7),3,5,13(17),14-hexaene-3,4-diol,GTPL33,(-)-10,11-Dihydroxyaporphine,VR-400,VR-040,APOMORPHINE [VANDF],R-(-)-Apomorphine,Biomol-NT_000019,SPBio_002021, MolPort-002-507-063,Uprima,(9R)-10-methyl-10-azatetracyclo[7.7.1.0^{2,7}.0^{13,17}]heptadeca-1(17),2,4,6,13,15-hexaene-3,4-diol,Apomorphine hydrochloride,Apomorphine (BAN),(apomorphine)6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol,(Apomorphine) 6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol,CHEBI:48538, 39478-62-1,APOMORPHINE [HSDB],(R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol (apomorphine),6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol ((R)-apomorphine),Apomorphine [BAN],6a.beta.-aporphine-10,11-diol,(R)-(-)-Apomorphine,DSSTox_GSID_22614,Kynmobi (sublingual film),BRD-K76022557-001-01-3,4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (R)-,Apomorphine,Q-200645,NCGC00025349-04,Uprima (TN),UNII-N21FAR7B4S,58-00-4 (free base), SCHEMBL6922802,Apormorphine,cid_6852399,VR004,Prestwick2_000101,NH001,Prestwick3_000101,(-)-Apomorphine,CHEMBL53, (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol,BDBM29644,Apomorphin, BDBM29643,Apomorfin,S-(+)-apomorphine,BDBM50001955, 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (S)-,DB00714,OR9, S-apomorphine

Estimated data

Solubilidad: -3.216 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 35.6% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.